The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a public alert warning healthcare providers, patients, and distributors about the circulation of falsified and unregistered versions of Dostinex 0.5mg tablets in Nigeria.
In Public Alert No. 07/2026, the agency disclosed that three affected batches are GG3470, LG8659, and GG2440 with expiry dates June 2027, January 2026, and April 2026 respectively, have been identified in circulation. The products, manufactured by Pfizer Italia S.R.L., Ascoli Piceno, Italy, reportedly carry no valid NAFDAC registration number.
Read also: Customs, NAFDAC Seize ₦3.7bn Fake, Expired Drugs
According to NAFDAC, Pfizer Nigeria Ltd, the Marketing Authorisation Holder, confirmed that falsified and parallel imported versions of the medicine are present in the country. The company also clarified that although the authentic product is registered, it has not yet been officially imported into Nigeria.
Dostinex 0.5mg is prescribed to reduce prolactin levels in patients. NAFDAC warned that falsified or unregistered medicines pose serious health risks because their safety, quality, and effectiveness cannot be guaranteed.
The agency has directed its zonal directors and state coordinators to intensify surveillance and remove the counterfeit products from circulation. Healthcare professionals, distributors, and retailers are advised to verify the authenticity of medical products and source medicines only from authorised suppliers.
NAFDAC urged the public and healthcare providers to report suspected counterfeit medicines or adverse reactions to the nearest NAFDAC office or through official reporting channels.
